Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kidswell BioTSE:4584 43 Debt-to-EBITDA is -2.48 as of Mar. 2026. GuruFocus rates TSE:4584 with a GF Score™ of 43/100 and a GF Value™ of 円279.79 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 298 Biotechnology companies, Kidswell Bio ranks worse than 335570.13% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Kidswell Bio's Debt-to-EBITDA or its related term are showing as below:
TSE:4584'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -7.21 Med: -1.32 Max: 15.81
Current: -7.21
During the past 13 years, the highest Debt-to-EBITDA Ratio of Kidswell Bio was 15.81. The lowest was -7.21. And the median was -1.32.
TSE:4584's Debt-to-EBITDA is ranked worse than 100% of 298
companies
in the Biotechnology industry
Industry Median: 1.15
vs TSE:4584: -7.21
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Kidswell Bio Debt-to-EBITDA Related Terms
Kidswell Bio Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Kidswell Bio's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4584 vs VRTX, REGN, RVMD: Debt-to-EBITDA Comparison
For the Biotechnology subindustry, Kidswell Bio's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kidswell Bio Debt-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Kidswell Bio's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Kidswell Bio's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Kidswell Bio (TSE:4584) has a Debt-to-EBITDA of -2.48 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Kidswell Bio. According to the industry distribution chart, Kidswell Bio ranks #999999 out of 298 companies in the Biotechnology industry.
Is Kidswell Bio's Debt-to-EBITDA too high?
Kidswell Bio's current Debt-to-EBITDA is -2.48. Based on the distribution chart, Kidswell Bio ranks #999999 out of 298 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Kidswell Bio has a GF Score™ of 43/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Kidswell Bio's Debt-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Kidswell Bio ranks #999999 out of 298 companies for Debt-to-EBITDA. This places Kidswell Bio in the lower half of its industry. The industry median Debt-to-EBITDA is 1.15. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Biotechnology company?
The median Debt-to-EBITDA among Biotechnology companies is 1.15, based on 298 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Kidswell Bio. For the Biotechnology industry, the median Debt-to-EBITDA is 1.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kidswell Bio's current Debt-to-EBITDA is -2.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kidswell Bio stock overvalued right now?
Based on GuruFocus' analysis, Kidswell Bio (TSE:4584) is currently considered Possible Value Trap. The stock's GF Value™ is 円279.79, compared to a current price of 円147.00 — trading 47.5% below its estimated fair value. The current Debt-to-EBITDA is -2.48. Kidswell Bio's overall GF Score™ is 43/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Kidswell Bio (TSE:4584), the current Debt-to-EBITDA is -2.48 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kidswell Bio (TSE:4584) Overvalued in 2026?
Based on GuruFocus' analysis, Kidswell Bio stock appears to be undervalued.
The current stock price of 円147.00 is trading 47.5% below its estimated GF Value™ of 円279.79.
GuruFocus considers Kidswell Bio to be Possible Value Trap.
Key valuation signals for TSE:4584:
Debt-to-EBITDA: -2.48
GF Value™: 円279.79 vs. price of 円147.00 (47.5% below fair value)
No single metric tells the full story. See the TSE:4584 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4584 has been successfully added to your 
